The 2026 BIO International Convention marked a turning point: for the first time, biotechnology was framed squarely as a matter of national security. This episode breaks down BIO CEO John Crowley's argument for why US innovation must confront Chinese competition head-on — from the "offensive" playbook of FDA modernization and tax incentives, to the "defensive" one of the BIOSECURE Act and outbound-investment controls. It also examines why Crowley, who could have played the easy anti-China card, instead points to America's own "man-made problems," and why he sees AI widening the divide between large and small players. A bilingual, two-sided look at a story being told very differently on each side of the Pacific.The 2026 BIO International Convention marked a turning point: for the first time, biotechnology was framed squarely as a matter of national security. This episode breaks down BIO CEO John Crowley's argument for why US innovation must confront Chinese competition head-on — from the "offensive" playbook of FDA modernization and tax incentives, to the "defensive" one of the BIOSECURE Act and outbound-investment controls. It also examines why Crowley, who could have played the easy anti-China card, instead points to America's own "man-made problems," and why he sees AI widening the divide between large and small players. A bilingual, two-sided look at a story being told very differently on each side of the Pacific.